

EDAP TMS S.A. Investor Relations Department 4 Rue du Dauphine Vaulx-en-Velin 69120 France

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: EDAP	
Last Trade:	3.15
Trade Time:	12:57 PM ET Jul 20, 2017
Change:	0.03 🛊 (+0.962%)
Day Range	3.11 - 3.18
52-Week Range	2.25 - 3.85
Volume	27,074

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

EDAP TMS is presently accelerating adoption of HIFU therapy as a new standard of care for localized prostate cancer in Europe where the company is the clear market leader while securing US approval through an active FDA Clinical Study at leading urology centers.

... (more)

Stock Performance



Press Releases [View all]

Jul 19, 2017

EDAP to Host Webcast Discussing HIFU
Devices with an American Key Opinion
Leader

Jul 17, 2017

EDAP Announces Withdrawal of 510(k)

Application for Focal One® to be Followed by

New Submission to Conform to FDA Review

Rules

May 22, 2017

EDAP Announces CMS Approval of New Reimbursement Code for HIFU Ablation of the Prostate

May 17, 2017

EDAP TMS SA Reports First Quarter 2017

Results

May 11, 2017

EDAP Announces Ablatherm Fusion World Premiere during American Urology Association Annual Meeting in Boston, MA, May 12-16, 2017

Upcoming Events [View all]

Jul 27, 2017 4:30 PM ET
EDAP-TMS (NASDAQ: EDAP) Webcast

Financials [View all]

Fourth Quarter Financial Results

Apr 3, 2017

Annual Report for Foreign Private Issuers (20-F)